Gálvez MAK, Padilla ÁS, Feregrino AJP, Núñez UJP, Vera UR

Language: Spanish
References: 3
Page: 293-295
PDF size: 1179.17 Kb.

ABSTRACT

Immune checkpoint inhibitors (ICI)-related myocarditis is quite an infrequent, but fatal, adverse effect with a reported incidence of 0.04-1.14%. Therefore, there are only a few cases in literature described thoroughly. Here we present a case report of a 51-year-old male with epidermoid lung carcinoma who, after being treated with nivolumab and ipilimumab, suffers a case of myocardiopathy secondary to ICI. In conclusion, we consider necessary the development of detailed guidelines for the treatment of this pathology whose incidence, as well as the use of ICI, shall increase.

REFERENCES

1. Sharma A, Alexander G, Chu JH, Markopoulos A, Maloul G, Ayub MT et al. Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials. J Am Heart Assoc. 2024; 13 (10): e032620. doi: 10.1161/JAHA.123.032620.

2. Lessomo FYN, Mandizadza OO, Mukuka C, Wang ZQ. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. Eur J Med Res. 2023; 28 (1): 495. doi: 10.1186/s40001-023-01464-1.

3. Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A et al. Comparison of original and 2018 lake louise criteria for diagnosis of acute myocarditis: results of a validation cohort. Radiol Cardiothorac Imaging. 2019; 1 (3): e190010. doi: 10.1148/ryct.2019190010.